Navigation Links
Genetics Determine Optimal Drug Dose of Common Anticoagulant
Date:8/21/2007

WASHINGTON, Aug. 21 /PRNewswire-USNewswire/ -- Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Society of Hematology. This result represents one of the first applications of using an individual's genetic information to guide personal medical care.

Because individuals metabolize drugs differently, varying doses of warfarin are needed for the drug to be effective in each patient. Too much warfarin can cause severe bleeding, and too little can cause dangerous blood clots. Currently, there is little guidance for predicting how much of the drug a person will need. Physicians have had to roughly estimate an initial dose of warfarin and then continually monitor a patient's International Normalized Ratio (INR) value (a measure of how fast the blood clots), during treatment to tweak the dosage by trial and error.

For the first time, a group of St. Louis researchers combined the standard INR method with genetic testing to predict the therapeutic warfarin dose. Since warfarin is often prescribed after major orthopedic surgery to prevent blood clots in the legs, the study followed 92 adults undergoing either total hip or knee replacement at the Washington University Medical Center, who had never previously taken the anticoagulant.

Prior to warfarin treatment, the researchers collected blood samples and each patient's medical history. The blood tests were used to examine variations in two genes, CYP2C9 and VKORC1, that may affect warfarin dosing. Variants in CYP2C9 impair the body's breakdown of warfarin; variants in VKORC1 cause increased warfarin sensitivity. The patients were assigned initial doses of warfarin based on clinical factors and their genotype. The researchers followed the patients until successful treatment outcomes were achieved several weeks later.

By combining
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Aug. 26, 2014 Research and ... "Global Veterinary Diagnostics Market 2014-2018" report ... include various tests, which are used to detect ... and biomedical researchers are mainly availing these diagnostic ... Acid/Ribonucleic Acid testing), immunodiagnostics, clinical chemistry, and hematology. ...
(Date:8/26/2014)... 2014 Using publicly released 2015 rate filings ... for five common specialty drugs. Specialty drugs have ... high costs and shortage of generic alternatives. They ... prescription, and are used for a broad variety ... HealthPocket found that among 2015 ...
(Date:8/26/2014)... , Aug. 26, 2014  Sorrento Therapeutics, ... late-stage clinical oncology company developing new treatments for ... it has received funding to advance an immunotherapy ... treatment of IPF, which affects more than 100,000 ... lungs increases and patients gradually lose the ability ...
Breaking Medicine Technology:Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 2Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 32015 Platinum Plans Are Best Buy for Consumers Using Expensive Specialty Drugs 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 3
... Maine, July 14, 2011 IDEXX Laboratories, Inc. (Nasdaq: ... its 2011 second quarter financial results for Friday, July ... conduct an analyst conference call beginning at 9:00 a.m. ... Individuals can access a live Webcast of the ...
... Biomedical Corporation (OTCBB:QTXB), an emerging leader in the ... on its patented technology platforms for the worldwide ... the lawsuit with NURX, its prior Joint Venture ... operations to expand its over-the-counter products and laboratory ...
Cached Medicine Technology:QuantRx Biomedical Settles Suit: Launches New PAD-Based Genomic Diagnostic Products 2QuantRx Biomedical Settles Suit: Launches New PAD-Based Genomic Diagnostic Products 3
(Date:8/27/2014)... Ellen V. Krieger, DDS released a new ... video is meant to describe the business and industry best ... over 28 years of cosmetic and family dentistry experience, Dr ... patients feel welcomed and cared for. , Dr. Krieger has ... years, building a solid reputation of offering bright, friendly service ...
(Date:8/27/2014)... Los Angeles, CA (PRWEB) August 27, 2014 ... Media Meetup event in collaboration with Diabetes Community Advocacy ... on October 24-25, 2014 at Embassy Suites LAX ... “DiabetesSisters’ Social Media Meetup featuring DSMA Live”, an event ... on Friday evening, October 24th. , Interactive in many ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 ... management, governance, and compliance software solutions for next-generation ... made Inc. magazine’s Inc. 500|5000, an exclusive ranking ... fifth consecutive year. AvePoint joins brands such as ... the 2014 edition. , This underscores continued ...
(Date:8/27/2014)... one of the most loved online bamboo product suppliers; the ... Recently, it has announced its new selection of bamboo ... to offer one-stop shopping solutions for people who want to ... is providing big discounts for all the brand new bamboo ... discounted price (up to 30% off) before the deadline on ...
(Date:8/27/2014)... CA (PRWEB) August 27, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... announced on August 1, that Organic Raw Carob Powder ... is recalled due to possible contamination with ... people with weakened immune systems. In healthy people it ...
Breaking Medicine News(10 mins):Health News:Ellen V. Krieger, DDS of McLean, Virginia Announces New Video Describing Industry Best Practices 2Health News:DiabetesSisters and Diabetes Community Advocacy Foundation Join Forces to Bring Together People with Diabetes in Los Angeles 2Health News:DiabetesSisters and Diabetes Community Advocacy Foundation Join Forces to Bring Together People with Diabetes in Los Angeles 3Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 2Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 3Health News:Brand New Bamboo Plywoods Now Offered At BambooIndustry.com 2Health News:Organic Raw Carob Powder by Sunburst SuperFoods Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Daiichi Sankyo, Inc. and Eli Lilly and ... the U.S. Food and Drug Administration (FDA) approved Effient(TM) ... (including stent thrombosis) in patients with acute coronary syndromes ... percutaneous coronary intervention (PCI). PCI usually includes the ...
... tip the scales toward more health risks, researcher says , FRIDAY, ... night, make you snap at your spouse and children, and make ... can also make you gain weight -- especially if you,re overweight ... people out, and stress has been linked to a number of ...
... a bi-national team of global health researchers at the University ... among male clients of female sex workers in Tijuana, has ... unprotected sex. They also reported a high prevalence of ... is necessary to prevent the spread of HIV and other ...
... ecological study of its kind in the world, a Wake ... finding that groundwater and airborne manganese in North Carolina correlates ... ... County in North Carolina: An Ecological Study," was published online ...
... July 10 Compirion Healthcare Solutions, a whole-hospital process improvement ... to help educate hospital executives, managers and clinicians in strategies for ... be found at www.compirion.com/webinars along with times, ... entitled Achieving Early AM Hospital Discharges: ...
... , WASHINGTON, July 10 The Department of Veterans ... design and build a free-standing spinal cord injury center ... The contract was awarded to the C3T Construction Company ... building will have a connecting tunnel, providing access to ...
Cached Medicine News:Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 2Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 3Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 4Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 5Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 6Health News:Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) 7Health News:Job Stress, Economy Weighing on Americans 2Health News:Risky sexual behavior among male clients of Tijuana sex workers heightens risk of HIV transmission 2Health News:Environmental manganese good in trace amounts but can correlate to cancer rates 2Health News:Compirion Healthcare Sponsors Free Webinar On Achieving Early Hospital Discharges 2Health News:Compirion Healthcare Sponsors Free Webinar On Achieving Early Hospital Discharges 3
... Bio-Modular total shoulder system is ... use in both hemiarthroplasty and ... Modularity in combination with a ... component options provide the surgeon ...
...
...
... Knee employs titanium alloy plasma spray ... fixation surface. Biomet's ArCom processed polyethylene ... proven bearing material. The Maxim Knee ... Modular tibial components offer excellent sizing ...
Medicine Products: